Controlling Health Care Costs States Take on Affordability — Hospital and Pharmaceutical Spending Are Pressing Priorities, but Difficult to Tackle Blog / Jan 26, 2023
Controlling Health Care Costs CMS Announces Public Comment and Engagement Opportunities in Medicare Drug Negotiation Process Blog / Jan 20, 2023
Controlling Health Care Costs Making Prescription Drugs Affordable: Options for the Center for Medicare and Medicaid Innovation Blog / Nov 10, 2022
Controlling Health Care Costs How Should Medicare Negotiate Drug Prices? A Summary of the Options Explainer / Oct 27, 2022
Controlling Health Care Costs Can State Prescription Drug Affordability Boards Address High-Cost Drug Prices? Blog / Oct 11, 2022
Controlling Health Care Costs The Federal 340B Drug Pricing Program: What It Is, and Why It’s Facing Legal Challenges Explainer / Sep 08, 2022
Controlling Health Care Costs The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending Issue Briefs / Jul 20, 2022
Controlling Health Care Costs The Accelerated Approval Pathway for New Drug Therapies: Controversies and Proposed Fixes Explainer / Jul 14, 2022
Controlling Health Care Costs Public Good vs. Private Gain: The Role of Public–Private Partnerships in Drug Innovation and Pricing Blog / Jun 08, 2022
Controlling Health Care Costs A Value-Based Approach to America’s Costly Prescription Drug Problem Blog / May 06, 2022
Controlling Health Care Costs Are Pharmacy Benefit Managers the Next Target for Prescription Drug Reform? Blog / Apr 20, 2022